News

Accelerating biopharmaceutical novelties: Körber joins the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Körber joins the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a community of biopharma manufacturers who are striving to do groundbreaking research in the field of big data, cell & gene and others to develop manufacturing capabilities in the USA.

Ruben Carbonell, Senior Technology Strategist, NIIMBL

Rachit Jain, Global Cell and Gene Lead Software, Körber Business Area Pharma

Lüneburg, Germany / Parsippany, NJ, USA, 14 April 2021. Körber joins the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a community of biopharma manufacturers who are striving to do groundbreaking research in the field of big data, cell & gene and others to develop manufacturing capabilities in the USA.

The new membership is an important step to strengthen networks and to achieve closer cooperation in leading biopharmaceutical production innovations. Körber is looking forward to contributing its expertise in areas such as big data and cell & gene therapy, but also creating strong connections with other members of the NIIMBL community that will strengthen advancements in the industry.

“We are happy to welcome Körber, a leading provider of services to the pharmaceutical industry including packaging, inspection and product handling technologies, to the NIIMBL member community. The software products and services portfolio of Körber’s Business Area Pharma, which includes the Werum PAS-X MES manufacturing execution system and the Werum PAS-X Savvy bioprocess data science software, will be a valuable addition to the innovation technologies available through our network,” says Ruben Carbonell, Senior Technology Strategist at NIIMBL.

Rachit Jain, Global Cell and Gene Lead Software at Körber Business Area Pharma, adds: “Continuing our mission to save patient’s lives, we are excited to join NIIMBL in its quest to solve most challenging problems in the biomanufacturing space such as big data and cell & gene therapy initiatives. In this community, Körber will work with community members such as the big pharmas but also with NIST, FDA, and BARDA etc. as we race towards revolutionizing biopharmaceutical manufacturing.”